These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24618238)

  • 1. [Glucose lowering drugs in case of impaired renal function].
    Assink MA; Abrahams AC; Rookmaaker MB
    Ned Tijdschr Geneeskd; 2014; 158():A6907. PubMed ID: 24618238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease.
    Nogueira C; Souto SB; Vinha E; Braga DC; Carvalho D
    Hormones (Athens); 2013; 12(4):483-94. PubMed ID: 24457396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
    Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V
    Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
    Scheen AJ
    Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving glycemic control in patients with type 2 diabetes and renal impairment.
    Avogaro A; Schernthaner G
    Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating type 2 diabetes in renal insufficiency: the role of pioglitazone.
    Fritsche L; Budde K; Glander P; Einecke G; Diekmann F; Schötschel R; Neumayer HH
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):488-91. PubMed ID: 14703956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin].
    Hasslacher C; Vogt C; Raupp D; Dreyhaupt J
    Dtsch Med Wochenschr; 2007 Nov; 132(47):2500-4. PubMed ID: 18027324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin analogues of patients with diabetes and renal impairment].
    Adamíková A
    Vnitr Lek; 2015 Feb; 61(2):147-50. PubMed ID: 25813259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
    Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.
    Hsiao PJ; Wu KL; Chiu SH; Chan JS; Lin YF; Wu CZ; Wu CC; Kao S; Fang TC; Lin SH; Chen JS
    Clin Exp Nephrol; 2017 Aug; 21(4):694-704. PubMed ID: 27599981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drugs affecting blood glucose in diabetic patients with renal failure.
    Charpentier G; Riveline JP; Varroud-Vial M
    Diabetes Metab; 2000 Jul; 26 Suppl 4():73-85. PubMed ID: 10922977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II Diabetes Patients with Proteinuria and the Recovery of Their Metabolic Parameters.
    Ya-Zhuo L; Keqi W; Xiang L; Bin C
    Cell Biochem Biophys; 2015 Dec; 73(3):593-5. PubMed ID: 27259298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.